2010-312 – The invention relates to the treatment of meningiomas using a composition including a cytotoxic agent and a compound selected from phenylbenzothiazole derivatives, stilbene derivatives, and biphenylalkyne derivatives.
2014-055 – Exon 41 of LRRK2 is floxed, thus LRRK2 can be removed by cre-mediated deletion. Genotype/Phenotype: homozygous LRRK2loxp/ LRRK2loxp, phenotype would be dependent on which cells express Cre after crossing. Utility: Parkinson’s Disease Research PMID: 22647713
2007-016 – Mouse expressing the human alpha-synuclein gene for the study of Parkinson’s disease. Genotype/Phenotype: These mice express the human alpha-synuclein gene, under the control of its endogenous human promoter and regulatory elements. Genomic multiplication of this locus in humans results in Parkinson’s disease with subsequent dementia, with post-mortem transitional or diffuse Lewy body... Read More
2003-128 – Human brain tumors that show invasive behavior in the brains of immunocompromised mice. Numerous, well-characterized tissue grafts are available.
2013-273 – Background: Aerobic fitness is one of the best predictors of all-cause mortality but not easily assessed on a large scale accurately. Technology Description: A web based health fitness assessment tool which may be carried out at any location and requires nothing more than a device camera, web portal, a step, and a chair. Using technology based light reflection and color spectrum, heart... Read More
2013-105 – The ε4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD) compared to the more common ε3 allele. Studies in animal models and humans suggest that apoE4 exhibits both loss-of-function and gain-of-toxic-function compared to apoE3. In regulating amyloid pathology, apoE4 is less efficient than apoE3 in mediating the clearance of... Read More
2012-253 – Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are devastating neurodegenerative diseases. FTLD results from the degeneration of the frontal and temporal lobes of the brain, and encompasses a group of disorders distinguished by abnormalities in behavior, language and personalityl. ALS is characterized by the degeneration of motor neurons, resulting in muscle... Read More
2012-098 – Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.
2012-004 – What is envisioned is a system of electrochemical and electrical monitoring coupled with directed stimulation to bypass damaged nerve tissue. The combination of information detection, conversion algorithm and programmed stimulation will provide regeneration of the neural commands. Further it is envisioned that a pump can be added to provide neural modular/growth factors to maintain the nerve... Read More
2010-333 – A major problem in the area of electrochemistry and fast scan cyclic voltammetry is the occurrence of multiple complex analytes being measured by the fast scan cyclic voltammetry. In this invention, we developed the technique of Double Pulse Voltammetry (DPV) in which very fast scan cyclic voltammetry can be done at various voltages in this case from -0.4 volt to +1.5 volt and back down... Read More
2009-126 – This invention includes the developement of inducible transgenic mice expressing human TDP-43 cDNA encoding the TAR-binding protein 43kD.
2009-125 – This invention includes the development of a homozygous transgenic mouse model expressing wild-type human TDP-43 cDNA encoding the TAR-binding protein 43kD endogenous levels.
WINCSWare: Two-way Wireless Communication Between Sensor and Control Unit for Data Aquisition and Selection of Sensing Parameters (Neurochemicals, Time, etc.) and Software for Processing of Incoming Data and Visual Display in Real-Time
2009-106 – Two-way Wireless Communication Between Sensor and Control Unit for Data Acquisition and Selection of Sensing Parameters (Neurochemicals, Time, etc.) and Software for Processing of Incoming Data and Visual Display in Real-Time.
WINCS Hardware & Combination of Amperometry and Voltametry in One System for Measuring Neurochemicals in Real-Time
2009-065 – Emerging evidence supports the hypothesis that modulation of specific central neuronal systems contributes to the clinical efficacy of deep brain and motor cortex stimulation. Real-time monitoring of the neurochemical output of targeted regions may therefore advance functional neurosurgery by, among other goals, providing a strategy for investigation of mechanism, identification of new... Read More
2009-064 – Previous studies had demonstrated the importance of adenosine in the mechanism of Thalamic DBS for Essential Tremor. Real-time monitoring of the neurochemical output of targeted regions may therefore advance functional neurosurgery by, among other goals, providing a strategy for investigation of mechanism, identification of new candidate neurotransmitters, and chemically guided placement of... Read More
2008-368 – We have generated a human neuronal culture to model formation of alpha-synuclein aggregates in Parkinson’s disease (PD) and dementia with Lewy bodies (DLBD). By engineering conditional expression of alpha-synuclein, we established a novel cell-based model 3D5, in which production of wild-synuclein was regulated by the tetracycline off inducible mechanism. Two to four weeks following... Read More
2008-163 – These mice conditionally express the human tau cDNA (4RON isoform) containing the FTDP-17 mutation (P301L) in exon 10. These mice utilize the TET-ON/TET-OFF® system to express approximately 7X human tau in comparison to murine tau. Both the tTA transgene (Memory Pharmaceuticals) and the tau transgene (Mayo) must be present to yield expression of the human tau. Doxycycline in the diet of the... Read More
2008-125 – Monoclonal antibodies were raised to human Abeta 1-42. The peptide used to immunize was Abeta 35-42. This antibody is also known as MM26-2.1.3 and also as clone MM26-126.96.36.199.86 and also as Ab42.2
2008-124 – Monoclonal antibodies were raised to human Abeta 1-16. The peptide used to immunize was fibrillar Abeta 1-42. This antibody is also known as AB42-5.
2008-123 – Monoclonal antibodies were raised to human Abeta 1-16. The peptide used to immunize was Abeta 1-16. This antibody is also known as Ab-9
2008-121 – Monoclonal antibodies were raised to human Abeta 1-16. The peptide used to immunize was Abeta 1-16. This antibody is also known as MM27-33.1.1
2008-120 – Monoclonal antibodies were raised to human Abeta 1-40. The peptide used to immunize was Abeta 35-40. This antibody is also known as MM32-13.1.1 and also as Ab40.1
2007-330 – We created mice that contain human LRRK2 cDNA encoding either the wild-type or G2019S mutant form of the gene (hereafter termed “responder line(s).” The cDNA in these animals has been placed behind a minimal CMV promoter containing TetO and will only produce human LRRK2 protein when combined (in bigenic mice) with tTA. We have demonstrated in COS7 cells that the human LRRK2 expression from... Read More
2007-288 – Mice in which the endogenous leucine-rich repeat kinase 2 gene (LRRK2) has been ablated. Exon 41 has been flanked with loxP sites to alow Cre-mediated deletion. The region deleted contains the serion/threonine protein kinase catalytic domain. Splicing of exon 40 to 42 causes a frameshift mutation with the introduction of an early stop codon (TGA).
2007-103 – The abnormal accumulation of TDP-43 protein has been recently identified as the major protein constituent for several neurodegenerative diseases. The protein undergoes several post-translational modifications including phosphorylation, ubiquitination and proteolytic cleavage. The pathologic accumulation of these truncated species is believed to be pathologic. Using cell culture models, we... Read More
2007-027 – Mice that over-express the human wild-type and mutant leucine-rich repeat kinase 2 gene (LRRK2).
2005-016 – These transgenic mice have regulatable tau expression and profound neurofibrillary pathology, neurodegeneration and memory impairment. The key features are (1) Protein expressed is human tau P301L; (2) Expression of transgenic tau is restricted to the forebrain; (3) Mice develop memory impairment by 2.5 months; (4) Mice develop argyrophilic neurofibrillary tangles by 4 months; (5) Mice... Read More
2001-023 – A novel expression system has been developed that selectively expresses ABeta40 or ABeta42 in the secretory pathway. This system enables expression of high levels of specific ABeta peptides. Such a system may be invaluable in developing animal models that critically determine the pathogenicity of individual ABeta peptides. In addition, the system may have general utility as a means of... Read More
2000-066 – We have created two lines of transgenic mice expressing human tau with the P301L mutation. Mice expressing the 2-3-10+ human isoform with the P301L mutation develop tau neurofibrillary tangles, motor deficits, and behavioral abnormalities. Mice expressing the longest human tau isofrom (2+3+10+) with the P301L mutation develop balloned neurons as well as neurofibrillary tangles. Motor and... Read More
1998-026 – Mutations in the tau gene have been discovered that are linked to Tau pathologies. Identification of these mutations can lead to animal models of neurodegenerative diseases to be developed and provides methods for determining a diagnosis of neurodegenerative disease in a patient.
1996-076 – Transgenic mouse (Tg2576) carrying the Swedish mutation for Alzheimer’s Disease. This mouse was developed by Dr. Karen Hsiao Ashe at the University of Minnesota and is exclusively licensed to Mayo. This mouse develops age-related neuropathology, including development of amyloid plaques and behavioral changes, and can be used in research related to Alzheimer’s Disease and other... Read More
1995-087 – The base sequence coding for the protein of the human kappa opioid receptor, the deduced amino acid sequence and the cell line transfected with the gene expressing the protein.
1993-058 – Open reading frame gene sequence of the neurotensin receptors from human brain tissue.